Pishvaian MJ, Lee MS, Ryoo B, et al. Updated safety and clinical activity results from a Phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). ESMO 2018, abstract LBA26.
Dinutuximab β plus lage dosis IL-2 na haplo-SCT bij gerecidiveerd neuroblastoom
mei 2023 | Neuro-oncologie, Stamceltransplantatie